Alzheimer's disease is a 21st century epidemic that currently affects more than 35 million people worldwide, with this number estimated to rise to 82 million by 2030. The fifth leading cause of death globally and the most common cause of dementia, Alzheimer's costs society upwards of $818 billion a year; yet despite significant research and investment, it remains an incurable disease.
Grifols' research into Alzheimer's began with a small clinical study into the potential of plasma exchange with albumin to slow the progression of the disease in mild and moderate AD patients.
More than a decade later, this research has become a phase 2b/3 clinical trial: AMBAR, Alzheimer Management by Albumin Replacement.
The AMBAR clinical trial has been carried out in 41 hospitals across the U.S. and Spain, in collaboration with some of the world's leading Alzheimer's research centers and organizations.
We have presented AMBAR (Alzheimer Management by Albumin Replacement) top line results (phase IIb/III) at the "Clinical Trials on Alzheimer's Disease" (CTAD) congress on October 27, 2018 in Barcelona.
+ 35 million
people world-wide suffer from Alzheimer's disease (AD)
of research on AD
+ €150 million
invested in AD research since 2004
It is currently estimated that 35 million people worldwide suffer from Alzheimer's, and this figure is continuing to grow.
Grifols and Alzheimer's
Since 2004, we have led a broad range of research initiatives on Alzheimer's.
The AMBAR hypothesis
AMBAR is an innovative treatment proposal aimed at slowing the progression of Alzheimer's disease through periodic plasma exchange.
AMBAR is an international and multicenter clinical trial designed by Grifols in collaboration with Fundació ACE in Barcelona, Spain; and the Alzheimer Disease Research Center in Pittsburgh, PA, U.S.